Author

Jean Andre Van Wyk

Observed names: J Van Wyk, J van Wyk, J. Van Wyk, J. van Wyk, Jean A van Wyk, Jean Van Wyk, Jean van Wyk, Van Wyk, Jean, van Wyk, J., van Wyk, Jean

Institution: ViiV Healthcare (United Kingdom)

Observed institutions: National Institutes of Health, University of Pittsburgh, Cornell University, Hospital Universitario La Paz, AbbVie (United States), Abbott (United States), MRC Clinical Trials Unit at UCL, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, ViiV Healthcare (United Kingdom), Hospital La Paz Institute for Health Research, Instituto Nacional de Salud Pública, National Institute of Allergy and Infectious Diseases, Centre hospitalier universitaire d'Orléans, AbbVie (United Kingdom), GlaxoSmithKline (Brazil), Abbott (France), Weill Cornell Medicine, Clínica Especializada Condesa Iztapalapa, University College London

ORCID: 0000-0001-5719-7949

Observed ORCID: 0000-0001-5719-7949

OpenAlex ID: A5019594570

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

2020 · Jean van Wyk, Faïza Ajana, et al. · Clinical Infectious Diseases · 282

PDF

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

2019 · Pedro Cahn, Juan Sierra Madero, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 215

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

2022 · Josep M Llibre, Carlos Brites, et al. · Clinical Infectious Diseases · 176

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

2021 · Shahin Lockman, Sean S Brummel, et al. · The Lancet · 164

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

2022 · Olayemi Osiyemi, Stéphane De Wit, et al. · Clinical Infectious Diseases · 139

PDF

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

2023 · Chloe Orkin, Jonathan M Schapiro, et al. · Clinical Infectious Diseases · 132

PDF

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

2023 · Moti N Ramgopal, Antonella Castagna, et al. · The Lancet HIV · 126

Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

2014 · Kevin Robertson, Carmen Bayon, et al. · AIDS Care · 112

PDF

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

2016 · Jean-Guy Baril, Jonathan B. Angel, et al. · PLoS ONE · 90

PDF

Barriers to access to care reported by women living with HIV across 27 countries

2015 · Margaret Johnson, Anna Samarina, et al. · AIDS Care · 84

PDF

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

2020 · Stephanie A. Ruderman, Heidi M. Crane, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 83

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

2017 · Nicholas I Paton, Nicholas I Paton, et al. · The Lancet HIV · 80

PDF

Antiretrovirals and Weight Change: Weighing the Evidence

2024 · David Alain Wohl, John R Koethe, et al. · Clinical Infectious Diseases · 76

PDF

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

2021 · Rickesh Patel, Lee Evitt, et al. · Infectious Diseases and Therapy · 68

PDF

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

2021 · Charlotte-Paige Rolle, Mezgebe Berhe, et al. · AIDS · 66

Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)

2016 · Zbyněk Straňák, Elie Saliba, et al. · PLoS ONE · 65

PDF

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort

2023 · Michael G. Sension, Laurence Brunet, et al. · Infectious Diseases and Therapy · 64

PDF

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

2020 · Jean van Wyk, Chloe Orkin, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 52

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

2022 · Parul Patel, Susan L. Ford, et al. · HIV Medicine · 49

PDF

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

2019 · Marta Boffito, Laura Waters, et al. · AIDS Research and Human Retroviruses · 46

PDF

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence

2021 · Y S Punekar, D Parks, et al. · HIV Medicine · 44

PDF

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

2017 · James G Hakim, Jennifer Thompson, et al. · The Lancet Infectious Diseases · 41

PDF

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

2022 · Josep M Llibre, Pedro E Cahn, et al. · Open Forum Infectious Diseases · 40

PDF

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

2019 · Beatriz Grinsztejn, Michael D Hughes, et al. · The Lancet HIV · 39

Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

2015 · Pat A. Tookey, Claire Thorne, et al. · BMC Infectious Diseases · 35

PDF

Works count: 114

Citation count: 2,997

H-index: 27

I10-index: 54